New pill hopes to ease rare mitochondrial disease
NCT ID NCT06644534
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an oral drug called TTI-0102 in 12 people with MELAS, a rare genetic disorder that causes muscle weakness, strokes, and fatigue. Participants receive either the drug or a placebo for 6 months. Researchers will measure walking ability, fatigue, and quality of life to see if the drug helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TTI-0102 (cysteamine-pantetheine disulfide)
What this could lead to
If it works, this could point toward a treatment that improves daily function and reduces fatigue for people with MELAS.
What could go wrong
This is a very small early-phase trial with only 12 participants, so results may not apply to everyone. The drug may not show clear benefit or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angers University Hospital Center (CHU Angers)
RECRUITINGAngers, 49100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Radboud University Medical Center
RECRUITINGNijmegen, 6500 HB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact